Baseline demographics and clinical characteristics
| Characteristic . | Pooled ASPEN cohort 1 and ALPINE (ASPEN/ALPINE) . | Pooled all patients treated with Zanubrutinib (N = 1550) . | |
|---|---|---|---|
| Zanubrutinib (N = 425) . | Ibrutinib (N = 422) . | ||
| Median age (range), y | 68 (35-90) | 68 (35-90) | 67 (20-95) |
| Age group, n (%) | |||
| ≥60 y | 331 (77.9) | 347 (82.2) | 1186 (76.5) |
| ≥65 y | 265 (62.4) | 274 (64.9) | 950 (61.3) |
| ≥65 and ˂75 y | 155 (36.5) | 181 (42.9) | 615 (39.7) |
| ≥75 y | 110 (25.9) | 93 (22.0) | 335 (21.6) |
| Sex, n (%) | |||
| Male | 280 (65.9) | 295 (69.9) | 1027 (66.3) |
| Female | 145 (34.1) | 127 (30.1) | 523 (33.7) |
| Race, n (%) | |||
| White | 348 (81.9) | 357 (84.6) | 1032 (66.6) |
| Asian | 49 (11.5) | 44 (10.4) | 424 (27.4) |
| Not reported | 17 (4.0) | 17 (4.0) | 42 (2.7) |
| Other | 11 (2.6) | 4 (0.9) | 51 (3.3) |
| Missing | 0 | 0 | 1 (0.1) |
| Geographic region, n (%)∗ | |||
| Europe | 259 (60.9) | 250 (59.2) | 551 (35.5) |
| Australia/New Zealand | 60 (14.1) | 60 (14.2) | 414 (26.7) |
| Asia | 45 (10.6) | 43 (10.2) | 406 (26.2) |
| North America | 61 (14.4) | 69 (16.4) | 179 (11.5) |
| Median BMI (range), kg/m2 | 26.1 (15.2-53.1) | 26.3 (18.0-44.6) | 25.5 (15.2-54.6) |
| ECOG PS, n (%) | |||
| 0 | 174 (40.9) | 164 (38.9) | 692 (44.6) |
| 1 | 239 (56.2) | 238 (56.4) | 763 (49.2) |
| 2 | 12 (2.8) | 20 (4.7) | 95 (6.1) |
| Diagnosis, n (%) | |||
| CLL/SLL | 324 (76.2) | 324 (76.8) | 938 (60.5) |
| WM | 101 (23.8) | 98 (23.2) | 249 (16.1) |
| MCL | - | - | 140 (9.0) |
| MZL | - | - | 93 (6.0) |
| FL | - | - | 59 (3.8) |
| DLBCL | - | - | 45 (2.9) |
| Other† | - | - | 26 (1.7) |
| Characteristic . | Pooled ASPEN cohort 1 and ALPINE (ASPEN/ALPINE) . | Pooled all patients treated with Zanubrutinib (N = 1550) . | |
|---|---|---|---|
| Zanubrutinib (N = 425) . | Ibrutinib (N = 422) . | ||
| Median age (range), y | 68 (35-90) | 68 (35-90) | 67 (20-95) |
| Age group, n (%) | |||
| ≥60 y | 331 (77.9) | 347 (82.2) | 1186 (76.5) |
| ≥65 y | 265 (62.4) | 274 (64.9) | 950 (61.3) |
| ≥65 and ˂75 y | 155 (36.5) | 181 (42.9) | 615 (39.7) |
| ≥75 y | 110 (25.9) | 93 (22.0) | 335 (21.6) |
| Sex, n (%) | |||
| Male | 280 (65.9) | 295 (69.9) | 1027 (66.3) |
| Female | 145 (34.1) | 127 (30.1) | 523 (33.7) |
| Race, n (%) | |||
| White | 348 (81.9) | 357 (84.6) | 1032 (66.6) |
| Asian | 49 (11.5) | 44 (10.4) | 424 (27.4) |
| Not reported | 17 (4.0) | 17 (4.0) | 42 (2.7) |
| Other | 11 (2.6) | 4 (0.9) | 51 (3.3) |
| Missing | 0 | 0 | 1 (0.1) |
| Geographic region, n (%)∗ | |||
| Europe | 259 (60.9) | 250 (59.2) | 551 (35.5) |
| Australia/New Zealand | 60 (14.1) | 60 (14.2) | 414 (26.7) |
| Asia | 45 (10.6) | 43 (10.2) | 406 (26.2) |
| North America | 61 (14.4) | 69 (16.4) | 179 (11.5) |
| Median BMI (range), kg/m2 | 26.1 (15.2-53.1) | 26.3 (18.0-44.6) | 25.5 (15.2-54.6) |
| ECOG PS, n (%) | |||
| 0 | 174 (40.9) | 164 (38.9) | 692 (44.6) |
| 1 | 239 (56.2) | 238 (56.4) | 763 (49.2) |
| 2 | 12 (2.8) | 20 (4.7) | 95 (6.1) |
| Diagnosis, n (%) | |||
| CLL/SLL | 324 (76.2) | 324 (76.8) | 938 (60.5) |
| WM | 101 (23.8) | 98 (23.2) | 249 (16.1) |
| MCL | - | - | 140 (9.0) |
| MZL | - | - | 93 (6.0) |
| FL | - | - | 59 (3.8) |
| DLBCL | - | - | 45 (2.9) |
| Other† | - | - | 26 (1.7) |
BMI, body mass index; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; MZL, marginal zone lymphoma.
Asia includes China (Mainland and Taiwan) and South Korea; Europe includes Austria, Belgium, Belarus, Bulgaria, Czech Republic, France, Germany, Greece, Italy, The Netherlands, Russian Federation, Poland, Spain, Sweden, Turkey, and United Kingdom; and North America includes the United States and Canada.
Includes 13 patients with Richter transformation, 11 patients with hairy cell leukemia, 1 patient with B-lineage lymphoma, and 1 patient with indolent lymphoma.